icad inc. (NASDAQ:ICAD)
icad inc. (NASDAQ:ICAD) represented a move of 0 percent or $0.05 per share and closed its previous day trading session at $4.08. 0 Shares were traded in the last trading session with an Average Volume of 69.5 Million Shares. The stock currently has a Market Capitalization of 60.26 Million.
Icad, Inc. designs, engineers, develops and manufactures digital image scanners, densitometers, film digitizers and related software for applications in the graphic arts, medical imaging and life sciences markets. The Company sells its products throughout the world through various distributors, resellers, systems integrators and OEM’s.
The stock traded between $2.42 and $4.68 over 1-Year time period showing its price to sales ratio of 2.27. icad inc. (NASDAQ:ICAD) is currently showing an INCREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $31.67 and 200-Day Simple Moving Average of $27.61. Its Price to Free Cash Flow is 0 and Price to Book of 7.03.
Analyst’s recommended the stock as 2 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, icad inc. (NASDAQ:ICAD) reported its Actual EPS of $-0.06/share. The analysts offering Earnings Estimates for the company were believing that icad inc. could bring EPS of $-0.08/share. The difference between Actual EPS and Estimated EPS was 0.02 Percent. Thus showing an Earnings Surprise of 25 Percent.
Trillium Therapeutics Inc. (NASDAQ:TRIL)
In the last trading session, Trillium Therapeutics Inc. (NASDAQ:TRIL) added its value by 0% closing at the price of $2.36. The stock currently has market capitalization of 34.1 Million, with average volume of 117.3 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Trillium Therapeutics Inc. (NASDAQ:TRIL) is showing beta of 0. This particular value of beta suggests that Trillium Therapeutics Inc. (NASDAQ:TRIL) has historically moved 0% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Trillium Therapeutics Inc. (NASDAQ:TRIL) is at $-2.55.
The stock currently has RSI of 33.45. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (do not eat) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (eat) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties.
Trillium Therapeutics Inc. (NASDAQ:TRIL) topped its 52-week high price of $11.50 on 12/11/17 and 52-Week Low Price of $ 2.28 on 11/14/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 16.19% and monthly volatility of 12.89% respectively.